Phase II study of topotecan and thalidomide in patients with high-risk myelodysplastic syndromes

References

• Raza A, Mundle S, Shetty V, Alvi S, Chopra H, Span L, et al. A paradigm shift in myelodysplastic syndromes. Leukemia 1996; 10: 1648–1652
   PubMed Web of Science ®Google Scholar
• Heaney M L, Golde D W. Myelodysplasia. N Engl J Med 1999; 340: 1649–1660
   PubMed Web of Science ®Google Scholar
• Greenberg P, Cox C, LeBeau M M, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079–2088
   PubMed Web of Science ®Google Scholar
• Kimby E, Nygren P, Glimelius B. A systematic overview of chemotherapy effects in acute myeloid leukemia. Acta Oncol 2001; 40: 231–252
   PubMed Web of Science ®Google Scholar
• Tohyama K, Tsutani H, Wano Y, Iwasaki H, Fukushima T, Urasaki Y, et al. Anti-leukemia chemotherapy of high-risk myelodysplastic syndromes. Oncologist 1997; 2: 160–163
   PubMedGoogle Scholar
• Buchner T, Hiddemann W, Berdel W, Wormann B, Loffler H, Schoch C, et al. Remission induction therapy: the more intensive the better?. Cancer Chemother Pharmacol 2001; 48(Suppl 1)S41–S44
   PubMed Web of Science ®Google Scholar
• Estey E. Incorporating new modalities into guidelines. Topotecan for myelodysplastic syndromes. Oncology (Huntingt) 1998; 12: 81–86
   PubMedGoogle Scholar
• Garcia-Carbonero R, Supko J G. Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins. Clin Cancer Res 2002; 8: 641–661
   PubMed Web of Science ®Google Scholar
• Cooper B W, Donaher E, Lazarus H M, Green S B, Gosky D M, Rosenthal N S, et al. A phase I and pharmacodynamic study of sequential topotecan and etoposide in patients with relapsed or refractory acute myelogenous and lymphoblastic leukemia. Leuk Res 2003; 27: 35–44
   PubMed Web of Science ®Google Scholar
• Mainwaring M G, Rimsza L M, Chen S F, Gomez S P, Weeks F W, Reddy V, et al. Treatment of refractory acute leukemia with timed sequential chemotherapy using topotecan followed by etoposide + mitoxantrone (T-EM) and correlation with topoisomerase II levels. Leuk Lymphoma 2002; 43: 989–999
   PubMed Web of Science ®Google Scholar
• Miller C B. Myelodysplastic syndromes. Curr Treat Options Oncol 2000; 1: 63–69
   PubMedGoogle Scholar
• Gore S D, Rowinsky E K, Miller C B, Griffin C, Chen T L, Borowitz M, et al. A phase II ‘window’ study of topotecan in untreated patients with high risk adult acute lymphoblastic leukemia. Clin Cancer Res 1998; 4: 2677–2689
   PubMed Web of Science ®Google Scholar
• Beran M, Estey E, O'Brien S M, Giles F J, Koller C A, Kornblau S, et al. Results of topotecan single-agent therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia. Leuk Lymphoma 1998; 31: 521–531
   PubMed Web of Science ®Google Scholar
• Kantarjian H M. New developments in the treatment of acute myeloid leukemia: focus on topotecan. Semin Hematol 1999; 36(Suppl 8)16–25
   PubMed Web of Science ®Google Scholar
• Beran M, Estey E, O'Brien S, Cortes J, Koller C A, Giles F J, et al. Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia. J Clin Oncol 1999; 17: 2819–2830
   PubMed Web of Science ®Google Scholar
• Beran M, Shen Y, Kantarjian H, O'Brien S, Koller C A, Giles F J, et al. High-dose chemotherapy in high-risk myelodysplastic syndrome: covariate-adjusted comparison of five regimens. Cancer 2001; 92: 1999–2015
   PubMed Web of Science ®Google Scholar
• Raje N, Anderson K C. Thalidomide and immunomodulatory drugs as cancer therapy. Curr Opin Oncol 2002; 14: 635–640
   PubMed Web of Science ®Google Scholar
• Steins M B, Padro T, Bieker R, Ruiz S, Kropff M, Kienast J, et al. Efficacy and safety of thalidomide in patients with acute myeloid leukemia. Blood 2002; 99: 834–839
   PubMed Web of Science ®Google Scholar
• Steins M B, Bieker R, Padro T, Kessler T, Kienast J, Berdel W E, et al. Thalidomide for the treatment of acute myeloid leukemia. Leuk Lymphoma 2003; 44: 1489–1493
   PubMed Web of Science ®Google Scholar
• Keravich D P, Daniels C E. Challenges of thalidomide distribution in a hospital setting. Am J Health Syst Pharm 1999; 56: 1721–1725
   PubMed Web of Science ®Google Scholar
• Thalomid® (thalidomide) Capsules [package insert]. Celgene Corporation, Warren, NJ 1993
   Google Scholar
• Armstrong D K. Topotecan dosing guidelines in ovarian cancer: reduction and management of hematologic toxicity. Oncologist 2004; 9: 33–42
   PubMed Web of Science ®Google Scholar
• Raza A, Yousuf N, Abbas A, Umerani A, Mehdi A, Bokhar S A, et al. High expression of transforming growth factor-beta long cell cycle times and a unique clustering of S-phase cells in patients with acute promyelocytic leukemia. Blood 1992; 79: 1037–1048
   PubMed Web of Science ®Google Scholar
• Raza A, Bokhari J, Yousuf N, Mehdi A, Mazewski C, Khan S, et al. Cell cycle kinetic studies in human cancers. Development of three DNA specific labels in three decades. Arch Pathol Lab Med 1991; 115: 873–879
   PubMed Web of Science ®Google Scholar
• Bennett J. World Health Organization classification of the acute leukemias and myelodysplastic syndrome. Int J Hematol 2000; 72: 131–133
   PubMed Web of Science ®Google Scholar
• Lisak L, Tahir S, Billmeier J, Willman D, Khan U, Pervaiz M, et al. Topotecan and thalidomide is an effective combination for a subset of patients with high-risk myelodysplastic syndromes (MDS). American Society of Clinical Oncology 39th Annual Meeting Program. Chicago, IL 31 May 2003 to 3 June, 2003
   Google Scholar
• Larson R A. Treatment of acute myeloid leukemia with antecedent myelodysplastic syndrome. Leukemia 1996; 10(Suppl 1)S23–S25
   PubMed Web of Science ®Google Scholar
• Garst J, Campagna L, Blackwell S, Kelley M, Padilla K, Bjusrtrom T, et al. A phase II study of sequential topotecan and carboplatin/etoposide for the treatment of extensive stage small cell lung carcinoma (SCLC). Proc Am Soc Clin Oncol 2003; 22: 661
   Google Scholar
• Mok T S, Wong H, Zee B, Yu K H, Leung T W, Lee T W, et al. A phase I-II study of sequential administration of topotecan and oral etoposide (topoisomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma. Cancer 2002; 95: 1511–1519
   PubMed Web of Science ®Google Scholar
• Silverman L R, Demakos E P, Peterson B L, Kornblith A B, Holland J C, Odchimar-Reissig R, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group B. J Clin Oncol 2002; 20: 2429–2440
   PubMed Web of Science ®Google Scholar